Navigation Links
Study finds injectable treatment for blood clots in advanced cancer patients increases
Date:2/14/2012

DENVER The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood clots, use of LMWH is low compared to another commonly used anticoagulant, warfarin.

The study was conducted by a team of Kaiser Permanente researchers from Colorado, Oregon, Washington and Northern California, Dana-Farber Cancer Institute and Group Health Research Institute.

Venous thromboembolism, or blood clots, are common and serious complications in cancer patients. Anticoagulation drugs work to prevent additional clots from forming, while the body partially or completely dissolves the initial clot.

The study examined data from electronic health records of four health plans participating in the Cancer Research Network, a consortium of integrated health plans that pool data for research. Patients were identified with advanced breast cancer, colorectal, lung and prostate cancer who received treatment between January 2000 and December 2008 at Group Health Cooperative and Kaiser Permanente regions in Colorado, Northern California and Oregon and Washington.

Over the entire study period, 25 percent of patients received LMWH as a primary treatment for blood clots. A majority of patients, 74 percent overall, received warfarin-based therapy.

"Blood clots are a frequent complication in patients with cancer, so it's essential to understand patterns of care and adherence to guideline recommendations for them," said Dr. Tom Delate, PhD, study lead author. "Current medical literature on this topic is limited, so our findings will add tremendously to this knowledge gap and, hopefully, stimulate discussions on the need for comparative effectiveness research evaluations between blood clot anticoagulation therapies."

A randomized controlled trial in July 2003 demonstrated that LMWH was more effective at preventing recurrent clots than warfarin in patients with cancer. In addition, current clinical guidelines from the American College of Chest Physicians, American Society of Clinical Oncology and National Comprehensive Cancer Network recommend LMWH treatment for cancer-related blood clots.

The study did not determine why warfarin continued to be the preferred anti-coagulation therapy for advanced cancer patients. Warfarin does have a long history of use in treatment of blood clots, and high-quality anticoagulation monitoring services are available in the health plans studied, possibly resulting in a high level of physician comfort with warfarin. In addition, because LMWH requires daily injections, patients may prefer taking warfarin since it is available in tablet form.

According to Dr. Delate, Clinical Pharmacy Research Scientist at Kaiser Permanente Colorado, next steps should be to study why use of LMWH is low compared to warfarin and to compare the effectiveness of LMWH compared with warfarin in patients with advanced cancer.


'/>"/>

Contact: Emily Schwartz
ESchwartz@GolinHarris.com
415-318-4371
Kaiser Permanente
Source:Eurekalert

Related medicine news :

1. Despite Treatment, Employees with Depression Generate Higher Absentee Costs, According to Thomson Reuters Study
2. American Council on Exercise (ACE) Study Reveals Kettlebells Provide Powerful Workout in Short Amount of Time
3. TV drama can be more persuasive than news program, study finds
4. Study carried out into biological risks of eating reptiles
5. Neuroimaging study may pave way for effective Alzheimers treatments
6. Study finds racial gaps continue in heart disease awareness
7. Luth Researchs IndicatorEDG(TM) Study Finds Americans Hopes of Achieving Their Dreams Are Fading
8. First blinded study of venous insufficiency prevalence in MS shows promising results
9. Soothing infants with food focus of childhood obesity study
10. People with anxiety disorder less able to regulate response to negative emotions, study shows
11. American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue in Heart Disease Awareness, Low Knowledge of Heart Attack Warning Signs Among Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Anahata ... Spiritual Awakening, is happy to announce her “Spring Rejuvenation in Sedona” personally ... individual customized retreats offer the winter-weary soul an excellent opportunity to come out ...
(Date:2/27/2017)... ... 2017 , ... Orange County dentist, Dr. A. Rassouli, comments on ... when the bacteria in plaque infect the gums and other tissues supporting the teeth. ... planing or SRP, and can include surgical therapies if the condition has led to ...
(Date:2/27/2017)... ... February 27, 2017 , ... Texas based ... In addition, Discount Power's RCE (Residential Customer Equivalent) count exceeds 150,000. ... company had 800 customers and 2,250 RCEs at the time of acquisition. In ...
(Date:2/27/2017)... ... , ... New Jersey ranks among the top five states in the entire ... for advanced services is growing. , Project WE vs C is a focused ... their non-profit partners in their fight against cancer and in support of their shared ...
(Date:2/26/2017)... San Mateo, CA (PRWEB) , ... February 26, 2017 , ... ... Bay Area cities as diverse as Millbrae, Belmont, and Palo Alto, is proud to ... San Mateo. Many Bay Area consumers look for home care close to home, and ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
(Date:2/24/2017)... , Feb. 23, 2017 Report analyzes the worldwide ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Latin America ... are provided for the period 2015 through 2022. Also, a ... and analytics are derived from primary and secondary research. Company ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market ... companies have joined forces, resulting in the founding of Pharma To ... Pharma To Market are pleased to announce their expansion into ... in Singapore . The company are delighted to ... Co-Director of the Singapore based entity. Joelle ...
Breaking Medicine Technology: